ARC-T Cells

BIOLOGICAL2 trials

Sponsors

Kite, A Gilead Company

Conditions

Acute Myeloid LeukemiaAutoimmune DiseasesMyelodysplastic SyndromesSolid and Hematological Malignancies

Phase 1

Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome.

Active, not recruitingNCT05457010

Kite, A Gilead CompanyAcute Myeloid Leukemia, Myelodysplastic Syndromes

Start: 2022-11-28End: 2026-10-01Target: 24Updated: 2026-10-02

Unknown Phase

Long-Term Follow-Up Study After Gene-Modified Cell Treatment in Kite Studies

Enrolling by invitationNCT05041309

Kite, A Gilead CompanySolid and Hematological Malignancies, Autoimmune Diseases

Start: 2021-12-15End: 2040-12-01Target: 1500Updated: 2026-09-21

Related Papers

Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2

Journal of Hematology & Oncology2026-04-27

Five-Year Outcomes of Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Treated with Brexucabtagene Autoleucel (Brexu-cel) in ZUMA-2 Cohorts 1 and 2

Blood2024-11-056 citations